Skip to content
value.today

Embecta Corp.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, -1.5% a year (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

A market value of $366 M means free cash flow growing 7.3% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.

Revenue grew -1.5% a year over the last three years.

Cash-flow value of the shares
$-353 M
-197% against the market value
Value of the whole business
$819 M
before net debt
Value from after year 10
44%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-6.47%-3.97%-1.47%1.03%3.53%
8.15%-218%-176%-124%-61%+15%
9.15%-243%-208%-166%-114%-51%
10.15%-262%-232%-197%-153%-100%
11.15%-277%-251%-220%-183%-138%
12.15%-289%-266%-239%-207%-168%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Healthcare: $1.8 B to $5.1 B, median $2.9 BPrice to salesPrice to sales of Healthcare: $1.4 B to $7.2 B, median $3.0 B$0 M$2.0 B$3.9 B$5.9 B$7.8 BMarket value $366 M

Your own DCF model

A full discounted-cash-flow model of Embecta Corp., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the sector Healthcare

Multiples of its companies with a market value at most 60 days old, times Embecta Corp.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Embecta Corp.Applied toValue (25th to 75th)Companies
P/E18.5× / 30.2× / 54.0×4.2×net income $95 M$1.8 B to $5.1 B218
Price to sales1.3× / 2.8× / 6.7×0.4×revenue $1.1 B$1.4 B to $7.2 B353

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Embecta Corp.'s multiples at each month end with a market cap on file, Dec 2022 to Oct 2026, each against its own median.

P/E

4.2×

Now below its median of 8.7×; range 1.7× to 15.3× over 27 months.

0×4×8×12×15×2023202420252026P/E 4×Median 9×

Price to sales

0.4×

Now below its median of 0.6×, in the bottom quarter of its range; range 0.2× to 1.4× over 27 months.

0×0×1×1×1×2023202420252026Price to sales 0×Median 1×

as of Oct 29, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 29, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Sep 30, 2025$1.1 B$95 M$192 M$9 M$182 M$1.2 BSEC annual report (10-K, 20-F)
FY2024to Sep 30, 2024$1.1 B$78 M$36 M$16 M$20 M$1.3 BSEC annual report (10-K, 20-F)
FY2023to Sep 30, 2023$1.1 B$70 M$68 M$27 M$41 M$1.3 BSEC annual report (10-K, 20-F)
FY2022to Sep 30, 2022$1.1 B$224 M$412 M$24 M$389 M$1.3 BSEC annual report (10-K, 20-F)
FY2021to Sep 30, 2021$1.2 B$415 M$456 M$37 M$420 M$0 MSEC annual report (10-K, 20-F)
FY2020to Sep 30, 2020$1.1 B$428 M$499 M$42 M$457 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $366 M on Oct 29, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.